Resolution of Allergic Inflammation

Resolution of Allergic Inflammation: Identification and Kinetics of Specific Lipid Mediators During Nasal Allergen Challenge

Status

Completed

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01992835

Enrollment

Registered

2013-11-25

Start date

2013-11-01

Completion date

2014-04-01

Last updated

2026-01-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Grass Pollen Allergic Rhinitis

Brief summary

After an allergen challenge, the allergic inflammatory response disappears spontaneously. The initiation of the resolution of the inflammatory response is now recognized as a dynamic process, involving active biochemical programs that enable inflamed tissues to return to homeostasis. Recent data established key roles of different specific lipid mediators in the endogenous counter-regulation of inflammation and activation of resolution. Only little is known about kinetics of these specialized pro-resolving lipid mediators during acute allergic inflammation. Therefore, the primary propose of our study is to characterize the temporal evolution of cellular inflammation and specific lipid mediators after allergen challenge.

Interventions

OTHERGrass pollen allergen extract

Each subject will be challenged with a grass pollen allergen extract and with placebo.

OTHERplacebo

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

OTHER

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

18 Years to 55 Years

Healthy volunteers

Inclusion criteria

Eligibility criteria: Inclusion Criteria * Allergic rhinitis during the grass pollen season with or without asthma, with at least one of the following symptoms: nasal congestion, itching, rhinorrhea, sneezing * Grass pollen sensitization determined by a positive skin prick test and / or presence of specific IgEs to a grass pollen allergen extract

Exclusion criteria

* Smoker * Specific immunotherapy with grass allergens or other respiratory allergen for inclusion. * Current exhibition to another clinically relevant respiratory allergen

Design outcomes

Primary

Measure	Time frame
Clinical nasal score and measurement of mediators in biological fluids	Measurement of mediators in biological fluids during 72 h after nasal allergen challenge
Clinical nasal score and measurement of mediators in biological fluids.	Measurement and indentification of specific lipid mediators during nasal allergen challenge

Countries

France

Contacts

PRINCIPAL_INVESTIGATORCindy Barnig

Pôle de Pathologie Thoracique- Hôpitaux Universitaires Strasbourg

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026